Fig. 5

MACC1 induced trastuzumab resistance and enhanced the Warburg effect in vivo. a Representative images of MACC1 protein immunostaining in two xenografts tumor tissue. Anti-MACC1 immunohistochemistry of two NCI-N87 xenografts tumor tissue. Black bar, 50 μm. b Pre-established NCI-N87 MACC1 overexpression or vector tumor xenografts (left) and NCI-N87 MACC1 downregulation or scramble tumor xenografts (right) were treated with Ttzm (10 mg/kg, i.p., 2 times/wk × 3 weeks). Arrow means begin to treat drugs. Data are presented as the tumor volume (mm³), n = 6. Statistical analysis using the Student’s t test. *P < 0.05, ^# P < 0.01, ⁺ P < 0.001. c Pre-established NCI-N87 MACC1 overexpression or vector tumor xenografts (upper), and NCI-N87 MACC1 downregulation or scramble tumor xenografts (below) were treated with Ttzm (10 mg/kg, i.p., 2 times/wk × 3 weeks) or PBS (10 mg/kg, i.p., 2 times/wk × 3 weeks). Arrow means begin to treat drugs. Data are presented as the tumor volume (mm³), n = 6. Statistical analysis using the multiple t test. *P < 0.05, ^# P < 0.01, ⁺ P < 0.001. d MicroPET demonstrates that MACC1 overexpression promotes ¹⁸F-FDG uptake in mice bearing NCI-N87 xenograft. R, right (MACC1 overexpression or downregulation); L, left (vector or scramble). White circles present the tumor location. e Representative IHC TUNEL staining of tumor tissue from mice bearing NCI-N87 xenografts pretreatment with and Ttzm